Effect Of Vitamin Intake Research Articles

Effects of Vitamin Intake on Blood Glucose in Cancer Patients Undergoing Chemotherapy: Quantitative and Descriptive Research

Effects of Vitamin Intake on Blood Glucose in Cancer Patients Undergoing Chemotherapy: Quantitative and Descriptive Research

Effect of Vitamin Intake on Cognitive Decline in Older Adults: Evaluation of the Evidence.

The objective of this review was to evaluate the evidence from human studies on the intake of vitamins, either as monotherapies or in combination with other vitamins, as neuroprotective agents that may delay the onset of cognitive decline in older adults. Evidence-based methodologies were used to capture and evaluate the highest levels of evidence. The current evidence available showed no association for cognitive benefits of vitamins B6 or B12 as a monotherapy, and recent systematic reviews provide no clear evidence that supplementation with vitamin B6, B12 and/or folic acid improves dementia outcomes or slows cognitive decline, even though it may normalise homocysteine levels. Meta-analyses from systematic reviews have shown an association between low vitamin D levels and diminished cognitive function, although causality cannot be confirmed from the available evidence. There is no convincing evidence for an association of vitamin A, vitamin C or vitamin E either as a monotherapy or in combination with other antioxidant vitamins such as β-carotene and the prevention of cognitive decline. The appraisal of nineteen systematic reviews and meta-analyses has highlighted the heterogeneity between studies, and the need for better consensus on definitions of cognitive decline, duration of testing and agreement on which specific endpoints are clinically relevant. Evaluation of the totality of the currently available evidence indicates that intake of the above vitamins, either as a monotherapy, or in combination with other vitamins, has no clinically-relevant effect on delaying cognitive decline or delaying the onset of dementia in older adults.

Sensitivity of the Finometer device in detecting acute and medium-term changes in cardiovascular function

The Finometer (FMS, Finapres Measurement Systems, Arnhem, Netherlands), which is the improved successor of the Finapres (TNO Biomedical Instrumentation, Amsterdam, Netherlands), measures finger arterial blood pressure non-invasively and computes other cardiovascular parameters from the computed aortic-flow waveform. The usability of the Finometer would depend on whether it is sensitive enough to detect small cardiovascular changes. The aim was therefore to determine the sensitivity of the Finometer regarding acute and longer-term cardiovascular changes. The sensitivity of the Finometer regarding the acute effect of 200 mg caffeine was determined with a double-blind, placebo-controlled crossover study which included 38 young male subjects. Finometer recordings were performed during four occasions at fasting level and after 30 min of ingestion. To evaluate the sensitivity of the Finometer in recording longer-term effects of a daily dosage of 1000 mg vitamin C, 800 mg vitamin E and 10 mg folic acid, 14 young males took placebo and 17 took the vitamins for 12 weeks in a double-blind study. Two recordings were performed at baseline and two after 12 weeks. After caffeine ingestion significantly (P<0.05) higher systolic, diastolic and mean blood pressure values than resting values were obtained. The arterial compliance was significantly lower after caffeine ingestion, whereas heart rate, peripheral resistance, stroke volume and cardiac output did not change significantly. No differences were shown after intake of placebo. Concerning the effects of vitamin intake, the vitamin group indicated a significant decrease in systolic blood pressure (P=0.03) whereas the placebo group indicated no significant differences after 12 weeks. The results suggest that the improved Finometer might be a sensitive instrument in the recording of relative small acute and longer-term changes in cardiovascular function, but more studies are necessary before final conclusions can be drawn.

A cross‐sectional study of vitamin intake in postoperative non‐small cell lung cancer patients

Background and Objectives: This cross-sectional study of postoperative non-small cell lung cancer (NSCLC) patients examined possible effects of vitamin intake and folate status on disease-free survival. Methods Supplemental vitamin usage, dietary vitamin intake (Willett Food Frequency Questionnaire), red blood cell (RBC) folate, and serum folate concentrations were assessed in patients with a history of NSCLC. Exclusion criteria included factors that alter folate status or that are associated with altered nutritional habits: (1) evidence of cancer on history, physical, or chest radiograph; (2) tobacco, alcohol ingestion (>2 drinks/day), or cancer treatment within 3 months; (3) use of folate antagonists; and (4) age <60 years. Results 36 subjects were evaluated. The median disease-free censored survival was 24 months (range 4–41). Nineteen of 36 patients (53%) reported vitamin supplementation. Vitamin users had a longer median censored survival compared with nonusers (41 months versus 11 months; P = 0.002). With adjustment for cancer stage, the association between RBC folate and censored survival (r = 0.35; P = 0.055) and between serum folate and censored survival (r = 0.32; P = 0.083) approached statistical significance. Conclusions NSCLC patients who took vitamin supplements were more likely to be long-term survivors in the patients studied; a similar trend toward long-term survival was seen among patients with higher circulating folate concentrations. J. Surg. Oncol. 68:231–236, 1998. © 1998 Wiley-Liss, Inc.

A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients.

This cross-sectional study of postoperative non-small cell lung cancer (NSCLC) patients examined possible effects of vitamin intake and folate status on disease-free survival. Supplemental vitamin usage, dietary vitamin intake (Willett Food Frequency Questionnaire), red blood cell (RBC) folate, and serum folate concentrations were assessed in patients with a history of NSCLC. Exclusion criteria included factors that alter folate status or that are associated with altered nutritional habits: (1) evidence of cancer on history, physical, or chest radiograph; (2) tobacco, alcohol ingestion (>2 drinks/ day), or cancer treatment within 3 months; (3) use of folate antagonists; and (4) age <60 years. 36 subjects were evaluated. The median disease-free censored survival was 24 months (range 4-41). Nineteen of 36 patients (53%) reported vitamin supplementation. Vitamin users had a longer median censored survival compared with nonusers (41 months versus 11 months; P = 0.002). With adjustment for cancer stage, the association between RBC folate and censored survival (r = 0.35; P = 0.055) and between serum folate and censored survival (r = 0.32; P = 0.083) approached statistical significance. NSCLC patients who took vitamin supplements were more likely to be long-term survivors in the patients studied; a similar trend toward long-term survival was seen among patients with higher circulating folate concentrations.